肉腫治療薬の世界市場

肉腫治療薬の世界市場は2030年までに24億米ドルに達する見込み

2023年に14億米ドルと推定される肉腫治療薬の世界市場は、分析期間2023-2030年にCAGR 7.5%で成長し、2030年には24億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 7.3％を記録し、分析期間終了までに19億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 8.4%と推定されます。

米国市場は3億9,350万米ドルと推定、中国はCAGR 7.0％で成長予測

米国の肉腫治療薬市場は、2023年に3億9,350万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.0%で推移し、2030年には3億6,880万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.9%と6.1%と予測されています。欧州では、ドイツがCAGR約6.1%で成長すると予測されています。

世界の肉腫治療薬市場- 主要動向と促進要因のまとめ

肉腫治療薬市場を形成する進歩とは？

肉腫は骨や軟部組織に発生するまれなタイプのがんであり、専門的な治療戦略が必要とされるため、肉腫治療薬の開発は複雑だが重要な取り組みとなっています。肉腫治療薬には、化学療法、免疫療法、標的療法、新たな遺伝子療法などが含まれます。肉腫の種類は多様で、50以上の亜型があるため、治療アプローチは非常に個別化されており、多くの場合、異なるがんの特徴に対処するために薬剤の種類を組み合わせる必要があります。製薬企業や研究機関は、患者の予後を改善する新たな治療法の発見に多大な投資を行っており、免疫療法や精密医療の進歩により、肉腫患者の予後や生存率の向上が期待されています。

肉腫治療薬市場の主要セグメントは？

主な薬剤の種類には、化学療法、標的療法、免疫療法があり、標的療法は、健康な細胞を温存しながらがん細胞を選択的に攻撃できることから支持を集めています。免疫療法、特にチェックポイント阻害剤も特定の肉腫サブタイプの治療には不可欠となっており、がんに対する身体の自然免疫反応を強化する有望なアプローチを提供しています。治療環境には病院、がんセンター、診療所が含まれるが、複雑な肉腫治療を実施するための高度な設備を有する病院が最大の市場シェアを占めています。肉腫治療薬市場の用途は、骨肉腫、脂肪肉腫、ユーイング肉腫などの肉腫のサブタイプにまたがっており、骨肉腫と軟部肉腫の治療は有病率が高いことから重要なセグメントを占めています。肉腫はすべての年齢層に発症する可能性があるが、特定のタイプは小児に多く発症するため、エンドユーザーには成人患者と小児患者が含まれます。小児肉腫の治療には特殊な薬剤が必要なため、製薬会社は小児に適した製剤の開発に投資しています。

肉腫治療薬は治療現場でどのように活用されていますか？

病院では、肉腫治療薬は併用療法に使用され、化学療法と標的治療薬や免疫療法薬を統合して治療効果を高めています。がんセンターでは、肉腫治療薬の臨床試験を専門に行うことが多く、標準的な診療ではまだ利用できないような革新的な治療法を患者に提供しています。特に都市部の診療所では、外来で肉腫の治療を行っており、大規模な入院なしに管理可能な治療に重点を置いています。さらに、肉腫腫瘍の遺伝的構成を決定するための高度な診断方法がますます使用されるようになっており、より個別化された効果的な薬物レジメンが可能となっています。

肉腫治療薬市場の成長を促進する要因は何か？

肉腫治療薬市場の成長は、研究資金の増加、腫瘍学の進歩、肉腫の診断率の上昇など、いくつかの要因によってもたらされます。免疫療法、分子標的治療、遺伝子治療などの技術革新は治療の選択肢を広げ、個別化医療へのシフトを後押ししています。生存率の向上、薬効の強化、副作用の最小化に焦点が当てられていることも、新規治療が患者に新たな希望をもたらすとして、需要をさらに押し上げています。さらに、臨床試験の増加、精密医療への投資、がん診断の進歩が市場開拓に寄与し、新しく効果的な肉腫治療薬の開発を促しています。

セグメント

治療タイプ（標的療法、化学療法）

調査対象企業の例（注目の合計42社）

• Amgen
• Bayer AG
• Eisai Co., Ltd.
• Eli Lilly
• Johnson and Johnson
• Novartis
• Pfizer Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Sarcoma Drugs Market to Reach US$2.4 Billion by 2030

The global market for Sarcoma Drugs estimated at US$1.4 Billion in the year 2023, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$393.5 Million While China is Forecast to Grow at 7.0% CAGR

The Sarcoma Drugs market in the U.S. is estimated at US$393.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$368.8 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Sarcoma Drugs Market - Key Trends and Drivers Summarized

What Advancements Are Shaping the Sarcoma Drugs Market?

Sarcoma, a rare type of cancer originating in the bones and soft tissues, requires specialized treatment strategies, making the development of sarcoma drugs a complex but critical endeavor. Sarcoma drugs include chemotherapy, immunotherapy, targeted therapies, and emerging gene therapies. Due to the diversity in sarcoma types, with over 50 subtypes, treatment approaches are highly individualized, often requiring a combination of drug types to address different cancer characteristics. Pharmaceutical companies and research institutions are heavily invested in discovering new treatments that can improve patient outcomes, with advancements in immunotherapy and precision medicine driving hope for better prognosis and survival rates in sarcoma patients.

What Are the Key Segments in the Sarcoma Drugs Market?

Key drug types include chemotherapy, targeted therapy, and immunotherapy, with targeted therapies gaining traction due to their ability to selectively attack cancer cells while sparing healthy cells. Immunotherapies, particularly checkpoint inhibitors, are also becoming essential for treating certain sarcoma subtypes, offering a promising approach that strengthens the body’s natural immune response against cancer. Treatment settings include hospitals, cancer centers, and clinics, with hospitals holding the largest market share due to their advanced facilities for administering complex sarcoma treatments. Applications in the sarcoma drugs market span across different sarcoma subtypes, such as osteosarcoma, liposarcoma, and Ewing sarcoma, with osteosarcoma and soft tissue sarcoma treatments representing significant segments due to higher prevalence rates. End-user segments include adults and pediatric patients, as sarcomas can affect all age groups, though certain types are more prevalent in children. Pediatric sarcoma treatment requires specialized drugs, prompting pharmaceutical companies to invest in developing pediatric-friendly formulations.

How Are Sarcoma Drugs Applied Across Treatment Settings?

In hospitals, sarcoma drugs are used in combination therapies, integrating chemotherapy with targeted or immunotherapeutic agents to enhance treatment efficacy. Cancer centers often specialize in clinical trials for sarcoma drugs, providing patients with access to innovative therapies that may not yet be available in standard practice. Clinics, particularly in urban areas, administer sarcoma treatments for patients in outpatient settings, focusing on therapies that are manageable without extensive hospitalization. Additionally, advanced diagnostic methods are increasingly used to determine the genetic makeup of sarcoma tumors, allowing for more personalized and effective drug regimens.

What Factors Are Driving the Growth in the Sarcoma Drugs Market?

The growth in the Sarcoma Drugs market is driven by several factors, including increased research funding, advancements in oncology, and a rising incidence of sarcoma diagnoses. Innovations in immunotherapy, targeted therapy, and gene therapy have expanded treatment options, supporting a shift towards personalized medicine. The focus on improving survival rates, enhancing drug efficacy, and minimizing side effects has further fueled demand, as novel therapies offer new hope for patients. Additionally, growth in clinical trials, investments in precision medicine, and advancements in cancer diagnostics have contributed to market expansion, encouraging the development of new and effective sarcoma drugs.

SCOPE OF STUDY:

The report analyzes the Sarcoma Drugs market in terms of US$ Thousand by the following Treatment Type, and Geographic Regions/Countries:

Segments:

Treatment Type (Targeted Therapy, Chemotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Amgen
• Bayer AG
• Eisai Co., Ltd.
• Eli Lilly
• Johnson and Johnson
• Novartis
• Pfizer Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Sarcoma Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Immunotherapy for Sarcoma Treatment Drive Market Growth
  • Rising Incidence of Rare Cancer Cases Spurs Demand for Sarcoma Drugs
  • Expansion of Orphan Drug Programs Strengthens Market Opportunity
  • Growing Use of Targeted Therapy Expands Treatment Options for Sarcoma
  • Increasing Investment in R&D for Rare Cancer Drugs Drives Market
  • Focus on Early Diagnosis and Treatment for Better Outcomes Spurs Demand
  • Growth in Biologics and Biosimilar Approvals Strengthens Market Potential
  • Advances in Precision Medicine for Cancer Treatment Boosts Sarcoma Drugs Market
  • Increased Support for Rare Disease Drug Development Propels Growth
  • Rising Awareness of Sarcoma Diagnosis and Treatment Expands Market
  • Increased Use of Gene Therapy in Cancer Treatments Spurs Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Sarcoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Sarcoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Sarcoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Sarcoma Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• JAPAN
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• CHINA
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• EUROPE
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Sarcoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Sarcoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Sarcoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• FRANCE
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• GERMANY
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Sarcoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Sarcoma Drugs by Treatment Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Sarcoma Drugs by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2024 & 2030

IV. COMPETITION